This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?
ADPD
Lisbon
2024
Symposium

Date and time:

08.03.24 at 11:10-12:50 UTC

Type:

Congress:
Speakers:

Welcome and introduction

Unravelling the pathophysiology of AD and PD: shared and distinct disease mechanisms

Pioneering solutions for challenges in PD

From basic research to real-life: translating the science to clinical practice

Guiding the research and treatment in AD and PD: what can we do to close current knowledge gaps?

Keeping people in mind: people living with AD and PD, and their care partners as a focus for drug development and better care

A clinician’s perspective: advancing our understanding with transcriptomics

Shaping the future of drug development in AD and PD: advancing people-centred care for tomorrow

properties.alt

Wiesje van der Flier

Amsterdam University Medical Centers (UMC), Amsterdam, Netherlands


Professor Wiesje van der Flier is full professor and scientific director of the Alzheimer Center Amsterdam at Amsterdam UMC, the Netherlands, where she has worked since 2004.

 

She studied neuropsychology at the University of Utrecht, Utrecht, the Netherlands. In addition, Professor van der Flier is a clinical epidemiologist. She leads the Amsterdam Dementia Cohort, an ongoing memory clinic-based cohort including more than 6000 patients with deep phenotyping (MRI, EEG, CSF biomarkers, and PET) and linked biobank (blood, DNA, CSF). The Amsterdam Dementia Cohort is at the basis of many of the studies performed at the Alzheimer Center Amsterdam.

 

She has been (co)promotor of >20 theses and is currently supervising ~10 PhD projects. Professor van der Flier’s main research areas are the origin of Alzheimer’s disease, its diagnosis and prognosis, and intervention and prevention. She leads ABOARD (A Personalized Medicine Approach for Alzheimer’s Disease), a Dutch public–private partnership of more than 30 partners.

 

Together with colleague Philip Scheltens, she has written a book, Het Alzheimermysterie, which was published by the Arbeiderspers.


Read full bio